Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post Marketing Observational Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice

NCT03659669 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03659669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03659669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post Marketing Observational Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice
Lead sponsor
AbbVie
Phase
Observational
Overall status
Suspended
Start date
February 10, 2019
Completion date
February 28, 2027
Enrollment
272 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia (cll)